Our CEO, Baroness Delyth Morgan, comments on draft guidelines issued today by NICE recommending pertuzumab (Perjeta) to treat HER2-positive breast cancer before surgery
NICE has today issued draft guidance not recommending pertuzumab (Perjeta) to treat HER2-positive breast cancer before surgery because it is uncertain how the responses to treatment seen in the clinical trials translate into long term benefits for patients.
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
“This is a disappointing but not unexpected decision. Perjeta before surgery has shown some promising early results, and could benefit up to 15% of breast cancer patients, but the clinical evidence is still insufficient.
“We sincerely hope this is what the new Cancer Drugs Fund and NICE’s ‘maybe’ option will be used for: to gather further data and allow patients access while this evidence is collected.
“We're concerned that the NICE appraisal process remains too inflexible to cope with the complexities of modern cancer drugs. We need the Prime Minister to intervene and review the appraisal system for new drugs, which has still not been significantly updated since 1999.”